No Data
Stocks that moved the previous day part2 lannett co inc, Fit Easy, Cloud W, etc.
Stock names 6th closing price ⇒ Significant vacuum compared to the previous day＜6962＞ 562 -52 Operating loss for the first half due to exchange rate losses. Duskin＜4665＞ 3770 -278 downward revision of performance and dividend estimates. Gree＜3632＞ 427 -38 Turning to an operating loss in the first quarter. FC Sea＜7296＞ 2694 -158 Although it rose sharply on the 5th due to a substantial increase in dividends, etc., Sus Spirits＜2222＞ 2049.5 -63.5 Feeling of exhaustion as the full-year plan remains unchanged.
Emerging markets stocks digest: Cloud W surged significantly, Flutter hit a year-to-date high.
<4599> Stem Rim 366 +11 rebounds significantly after 5 days. The application patent for a peptide medicine created from the lead compound derived from HMGB1, a regenerative medicine candidate for Shionogi <4507>, has been announced to be registered in Japan. The patent secures the potential for developing a therapeutic drug for inflammatory bowel diseases (ulcerative colitis, Crohn's disease). Ledasemtide has effects such as suppressing weight loss in animal models of inflammatory bowel diseases and suppressing inflammation.
Active and newly listed stocks during the morning session.
*Enplus <6961> 5550 +550, Ichiboshi Securities upgrades its investment rating. *Itoki <7972> 1606 +146, turns to operating profit increase in the third quarter cumulative total. *Kyushu FG <7180> 778 +70.5, upward revision of performance and dividends estimates. *JMDC <4483> 4633 +368, first half exceeds previous plans. *Fujimi Incorporated <5384> 2504 +186, evaluates substantial increase in first half earnings. *Nomura Micro
Stem inc - significantly rebounded after 5 days, regenerative induction medicine Ledacemtide created peptide patented in japan.
It rebounded significantly after 5 days. It has been announced that a patent for the application of peptide drugs created from the regenerative induction pharmaceutical development candidate Ledacemtide (HMGB1) derived to Shionogi <4507> has been registered in japan. The patent secures the possibility of developing therapeutic drugs for inflammatory bowel diseases (ulcerative colitis, Crohn's disease). Ledacemtide has shown effects such as suppressing weight loss in animal models of inflammatory bowel diseases and suppressing inflammation.
Renaissance, stem inc rim, and others.
Upward revision, previous operating profit outlook 0.063 billion yen ← 0.025 billion yen.
StemRIM: Confirmation letter
No Data
No Data